Idera Pharmaceuticals Reports Clear Disease Control

Idera Pharmaceuticals Reports Clear Disease Control

Idera Pharmaceuticals (IDRA) reported Sunday that 6 out of 9 melanoma patients, or 67%, experienced clear disease control when treated with IMO-2125, the company’s intratumorally-delivered Toll-like Receptor (TLR) 9 agonist, in combination with Bristol-Myers Squibb’s (BMY) Yervoy, or ipilimumab; overall response rate was 44%. The company said that the data was positive and encouraging as majority of patients with solid tumors do not respond to anti-PD-1 therapy and the published […]

Read More ˃
Amphenol’s Price Target Boosted by RBC to $85 From $81, Rating Kept at Top Pick

Amphenol’s Price Target Boosted by RBC to $85 From $81, Rating Kept at Top Pick

Amphenol (APH) received a price-target boost Tuesday from RBC Capital Markets following meetings the firm held with the CEO and CFO of the provider of electrical, electronic and fiber optic connectors. The new price target is $85 per share, up from $81. This moves the target further above the stock’s Monday closing price of $79.75 as well as its 52-week high of $80.14. Following the meeting with Amphenol’s management, RBC […]

Read More ˃
YuMe Shares Slightly Higher

YuMe Shares Slightly Higher

YuMe shares were higher 2% on Wednesday as UK-listed RhythmOne plc confirmed that it is in discussions about a possible takeover of the provider of multi-screen video advertising technology. RhythmOne said that there can be no certainty that any transaction will proceed. YUME earlier traded as high as $5.70, just $0.15 short of the 52-week high of $5.85. The 52-week low is at $3.11.

Read More ˃
Conatus Pharmaceuticals Completes Enrollment in Phase 2n Study

Conatus Pharmaceuticals Completes Enrollment in Phase 2n Study

Conatus Pharmaceuticals said late Monday it has completed enrollment in a phase 2b study of emricasan in approximately 330 patients with biopsy-confirmed nonalcoholic steatohepatitis and stage 1 to 3 fibrosis. The primary endpoint of the study is a biopsy-based improvement in fibrosis by at least one stage compared to placebo using NASH CRN without worsening of steatohepatitis. Secondary endpoints include resolution of steatohepatitis without worsening of fibrosis, nonalcoholic fatty liver […]

Read More ˃
Cone Midstream Partners Q2 EPS Beats Street View as Revenues Fall Short

Cone Midstream Partners Q2 EPS Beats Street View as Revenues Fall Short

Cone Midstream Partners LP, a midstream energy assets company, reported Q2 net income per limited partner unit of $0.44, up from $0.39 for the same period last year, and ahead of the Capital IQ consensus forecast of $0.41. Total revenues for the quarter were $56.5 million, down from $58.4 million on the year-ago quarter, but short of he analyst forecast of $60.2 million. For full-year 2017, the company forecasts net […]

Read More ˃